Integrity Score 1621
No Records Found
No Records Found
No Records Found
About a week back US FDA authorized a lower dose of Regeneron’s antibody cocktail to treat COVID-19, which the company said may help more patients access the treatment.
In an updated emergency use authorization (EUA), the FDA lowered the dose to 1,200 mg — 600 mg of casirivimab and 600 mg of imdevimab — which is half the dose that was authorized under the original EUA issued in November.
Today Apollo MD Dr Sangita Reddy who tested positive and reported very high fever as Covid symptom tweeted that the antibody cocktail helped .
REGEN-COV is available for free from the U.S. government to treat patients aged 12 years or older with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death.
In April this year Regeneron Pharmaceuticals announced a dual win for its single-dose monoclonal antibody cocktail as Phase IIIa/b trials found the injection effective in both preventing Covid-19 infections and halting the disease’s progression in asymptomatic patients.
The case for an antibody therapy as an alternative prevention method alongside the many vaccines now being rolled out is that it can offer readily available immune protection as, for a vaccine to work, recipients need to have a strong enough immune system to produce coronavirus-fighting antibodies by themselves, a process that takes time.